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Uncontrolled fibroblast growth factor (FGF) signaling
can lead to human malignancies necessitating mul-
tiple layers of self-regulatory control mechanisms.
Fibroblast growth factor receptor (FGFR) autoinhibi-
tion mediated by the alternatively spliced immuno-
globulin (Ig) domain 1 (D1) and the acid box (AB)-
containing linker between D1 and Ig domain 2 (D2)
serves as the first line of defense tominimize inadver-
tent FGF signaling. In this report, nuclear magnetic
resonance and surface plasmon resonance spec-
troscopy are used to demonstrate that the AB subre-
gion of FGFR electrostatically engages the heparan
sulfate (HS)-binding site on the D2 domain in cis to
directly suppress HS-binding affinity of FGFR. Fur-
thermore, the cis electrostatic interaction sterically
autoinhibits ligand-binding affinity of FGFR because
of the close proximity of HS-binding and primary
ligand-binding sites on the D2 domain. These data,
together with the strong amino acid sequence con-
servation of the AB subregion among FGFR ortho-
logs, highlight the universal role of the AB subregion
in FGFR autoinhibition.
INTRODUCTION
The mammalian fibroblast growth factors (FGFs) comprise a
family of 18 ligands that signal through four FGF receptor tyro-
sine kinases (FGFR1–4) and their alternatively spliced isoforms
(Johnson and Williams, 1993) to regulate embryonic develop-
ment and adult metabolism (Beenken and Mohammadi, 2009;
Goldfarb, 2005; Itoh and Ornitz, 2011; Kuro-o, 2008). Fibroblast
growth factors adopt a b-trefoil fold consisting of 12 antiparallel b
strands (b1–b12) (Faham et al., 1998; Mohammadi et al., 2005b).
The heparan sulfate (HS)-binding site (HBS) of FGFs comprises
residues from the b1-b2 loop and the b10-b12 region (Goetz
et al., 2007).Structure 20,The extracellular region of a prototypical FGFR consists
of three immunoglobulin (Ig)-like domains (D1, D2, and D3)
connected by flexible linkers (Plotnikov et al., 1999). A unique
characteristic of FGFRs is a stretch of glutamate-, aspartate-,
and serine-rich sequence situated in the D1-D2 linker, termed
the acid box (AB; Johnson and Williams, 1993; Figures 1C
and 1D). The segment spanning D2 and D3 (referred to as
D2-D3 region) is necessary and sufficient for ligand binding
and specificity (Mohammadi et al., 2005b). The HBS of FGFR
is comprised of basic amino acids from the g-helix A, b strands
B and D, and the gA-bA0 and bA0-bB loops—all of which localize
onto one face of D2 (Schlessinger et al., 2000; Figure 1B).
HS promotes 1:1 FGF-FGFR binding and stabilizes formation
of a 2:2 FGF-FGFR signal transducing dimer (Schlessinger et al.,
2000) in which receptor and ligand from one 1:1 FGF-FGFR pro-
tomer interacts with the receptor from the other 1:1 FGF-FGFR
protomer (Figure 1A). Heparan sulfate interacts concomitantly
with the juxtaposed HBS of the FGFR D2 domains and of the
FGF ligands to enhance protein-protein contacts at the dimer
interface, thereby sustaining dimerization (Mohammadi et al.,
2005a; Figure 1A). Dimerization enables tyrosine transphosphor-
ylation of the intracellular kinase domains, which upregulates
kinase activity (Chen et al., 2008; Mohammadi et al., 1996) and
generates docking sites for recruitment and phosphorylation
of downstream signaling substrates, ultimately culminating in
gene expression changes and biological responses (Eswaraku-
mar et al., 2005).
Tissue-specific alternative splicing of the D3 domain of
FGFR1-3 gives rise to epithelial ‘‘b’’ and mesenchymal ‘‘c’’ iso-
forms of these FGFRs (Jin et al., 2004; Orr-Urtreger et al., 1993;
Xu et al., 1998). This splicing event controls ligand-binding spec-
ificity of FGFRs by altering the primary sequences of key ligand-
binding regions in the C-terminal half of D3 (Mohammadi et al.,
2005b; Olsen et al., 2006; Yeh et al., 2003; Figure 1C). Skipping
of exons encoding D1 and/or the AB-containing linker between
D1 and D2 (abbreviated as AB/linker in the following text) gener-
ates isoforms lacking D1 (FGFR1c, FGFR1b, and FGFR2c), AB/
linker (FGFR3c), or both D1 and AB/linker (FGFR2b; Hou et al.,
1992; Shimizu et al., 2001; Xu et al., 1992). Loss of D1 or AB/linker
enhances the affinity of FGFR for FGF and HS and increases the
signaling capacity of FGFR, demonstrating that this alternative77–88, January 11, 2012 ª2012 Elsevier Ltd All rights reserved 77
Figure 1. FGF, FGFR, and HS Form a Symmetric 2:2:2 Dimer and Alternative Splicing of the AB/linker Region of FGFR Autoinhibits FGFR
Activation and Signaling
(A) Surface representation of the 2:2:2 FGF2-FGFR1c-heparin complex structure (PDB ID 1FQ9; Schlessinger et al., 2000). Themolecular surfaces of D2, D3, and
FGF are colored green, blue, and gray, respectively. Heparin oligosaccharides are shown as sticks.
(B) The surface charge distribution of the D2-D3 region of FGFR1c is shown (PDB ID 1FQ9; Schlessinger et al., 2000). Blue, red, and white represent the positively
charged, negatively charged, and neutral regions, respectively.
(C) Schematic representation of the two alternatively spliced FGFR3c isoforms with and without the AB/linker region. The AB subregion within the AB/linker is
indicated by a black box. The dashed lines show the boundaries of the exon encoding the 23-residue long AB/linker region in panel D. The HBS of the receptor is
confined to D2 and is highlighted in cyan. Two alternatively spliced exons (IIIb and IIIc) code for the C-terminal half of D3.
(D) Amino acid sequence of the FGFR3c extracellular domain. Secondary structure elements are indicated atop of the sequence. Secondary structures for D2 and
D3 are based on the crystal structure of FGF1-FGFR3c (PDB ID 1RY7; Olsen et al., 2004) and for D1 are based on the solution structure of FGFR1c D1 (PDB ID
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Acid Box-Mediated FGF Receptor Autoinhibitionsplicing event controls receptor autoinhibition (Olsen et al., 2004;
Roghani and Moscatelli, 2007; Shi et al., 1993; Shimizu et al.,
2001;Wang et al., 1995; Xu et al., 1992). Consistentwith the auto-
inhibitory role of D1 and AB/linker in receptor regulation, loss
of these regions has been implicated in cancer (Kobrin et al.,
1993; Mansson et al., 1989; Onwuazor et al., 2003; Tomlinson
and Knowles, 2010; Yamaguchi et al., 1994).
The molecular mechanism by which D1 and AB/linker impose
receptor autoinhibition is controversial. McKeehan and col-
leagues (Wang et al., 1995) proposed that the AB/linker serves
merely as a ‘‘passive’’ flexible hinge enabling D1 to intramolecu-
larly engage ligand- and HS-binding sites on the D2-D3 region
to suppress both ligand- and HS-binding affinity of the receptor
(Wang et al., 1995). Calculation of the surface electrostatic poten-
tial of the first FGF-FGFR complex structure solved in our labora-
tory showed that the HBS on D2 forms a contiguous positively
charged surface (Plotnikov et al., 1999; Figure 1B). Based on
this observation, we proposed that the negatively charged AB
subregion of the AB/linker electrostatically engages the positively
charged HBS of D2 to suppress HS binding. We further specu-
lated that the electrostatic interactions of AB with D2 may in turn
encourage intramolecular interactions of D1 with ligand-binding
sites in the D2-D3 region to suppress ligand binding (Olsen
et al., 2004). Hence, in stark contrast to the model proposed by
McKeehan and colleagues (Wang et al., 1995), in our model the
AB/linker region plays an active role in FGFR autoinhibition.
In this study, we explored the role of the AB/linker in FGFR
autoinhibition in cis by nuclear magnetic resonance (NMR) and
surface plasmon resonance (SPR) spectroscopy. Our data
show that the AB subregion of the AB/linker electrostatically
engages the HS-binding site on the D2 domain in cis, thereby
directly suppressing HS-binding affinity of the receptor. The cis
AB:HBS interaction also sterically autoinhibits ligand binding to
the receptor because of the close proximity of the HBS and
the ligand-binding site on the D2 domain. Hence, our data reveal
that the AB subregion plays a key role in FGFR autoinhibition.
RESULTS
AB/Linker-Imposed Receptor Autoinhibition Is an
Intrinsic Property of the Isolated FGFR3c Ectodomain
Alternative splicing of FGFR3c gives rise to two isoforms in vivo
that differ only in the presence of the AB/linker region (Figures 1C
and 1D; Shimizu et al., 2001). Cell-based studies have previously
established that, compared to the isoform containing the AB/
linker, the isoform lacking this region requires 3- to 4-fold lower
concentration of HS to elicit the same level of proliferation in
BaF3 cells (Shimizu et al., 2001). Moreover, at any given HS
concentration, the mitogenic response of BaF3 cells expressing
the isoform without the AB/linker to FGF8 and FGF9 is about
2-fold greater than that of the cells expressing the full-length
receptor (Shimizu et al., 2001). Therefore, FGFR3c is an optimal
FGFR for structural characterization of the role of the AB/linker in
FGFR autoinhibition.2CKN; Kiselyov et al., 2006a). The residues comprising the primary ligand-bindi
secondary ligand-binding site as predicted based on the 2:2:2 FGF2-FGFR1c-hep
by red and green boxes, respectively. Residues located at the receptor:receptor in
the 2:2:2 FGF2-FGFR1c-heparin complex, are highlighted by gray and dark blue
Structure 20,We have previously shown that an FGFR3c ectodomain frag-
ment lacking D1 and the AB/linker region binds FGF1 and
heparin with higher affinities than the full-length FGFR3c ectodo-
main (D1-AB-D2-D3) does (Olsen et al., 2004), demonstrating
that the presence of D1 and AB/linker autoinhibits FGFR3c.
Since an FGFR3c isoform lacking both D1 and the AB/linker
does not occur naturally, we decided to compare heparin/HS-
and ligand-binding affinities of D1-AB-D2-D3 with those of the
D1-D2-D3DAB/linker ectodomain, which represents the naturally
occurring isoform of FGFR3c lacking the AB/linker. The ectodo-
main constructs were expressed in Escherichia coli (E. coli;
Table S1 available online) and refolded from bacterial inclusion
bodies and purified to homogeneity using heparin affinity and
size-exclusion chromatographies (Figure S1). SPR spectros-
copy was then used to compare FGF and HS binding affinities
of the two ectodomains (Figure 2). For HS binding analysis,
heparin was coupled to a biosensor chip and increasing concen-
trations of D1-AB-D2-D3 or D1-D2-D3DAB/linker were passed over
the chip (Figures 2A and 2B). For ligand binding analysis, two
well-known cognate ligands of FGFR3c, namely, FGF1 and
FGF8b, were immobilized on biosensor chips, and increasing
concentrations of either of the two receptor ectodomains were
flowed over the chips (Figures 2C–2F). D1-D2-D3DAB/linker bound
heparin with almost 3-fold higher affinity than D1-AB-D2-D3
(Table 1; Figures 2A and 2B). D1-D2-D3DAB/linker also bound
the FGF ligands with about 2-fold greater affinity than D1-AB-
D2-D3 (compare Figures 2C and 2E with Figures 2D and 2F,
respectively). To our knowledge, these data show for the first
time that the AB/linker-imposed receptor autoinhibition occurs
in the context of the isolated FGFR3c ectodomain, i.e., in the
absence of transmembrane and cytoplasmic regions of receptor
or any accessory ‘‘extrinsic’’ cellular proteins/factors. Our SPR
data are consistent with the published cell-based data (Shimizu
et al., 2001), demonstrating that the presence of the AB/linker
region autoinhibits FGFR3c signaling by suppressing the recep-
tor’s affinity for FGF and HS.
Having confirmed the existence of AB/linker-mediated
FGFR3c autoinhibition in the context of the isolated receptor
ectodomain, we then expressed and purified uniformly
15N-labeled D1-AB-D2-D3 and D1-D2-D3DAB/linker constructs
and recorded their 1H-15N-HSQC spectra. Analysis of the
1H-15N-HSQC spectra of 15N-labeled D1-AB-D2-D3 and D1-
D2-D3DAB/linker, however, showed that neither of the two ectodo-
main constructs is tractable by NMR (Figures S2B and S2C).
First, out of 340 expected backbone amide peaks for the
D1-AB-D2-D3 construct, only 290 were observed. Similarly,
only 180 out of 318 expected peaks were observed for the
D1-D2-D3DAB/linker construct. Second, line shape and intensity
of the observed peaks were nonuniform, and a large number
of peaks were clustered between 7.6 and 8.6 ppm, a region
referred to as random coil region in NMR spectroscopy (Figures
S2B and S2C). Since approximately two-thirds of the expected
backbone amide proton peaks for each construct were resolved,
we suspected that one of the three Ig domains was responsibleng site as experimentally determined by the FGF1-FGFR3c structure, and the
arin complex structure (PDB 1D IFQ9; Schlessinger et al., 2000), are highlighted
terface and the HBS of FGFR3c, as predicted based on the crystal structure of
boxes, respectively. See also Figure S1 and Table S1.
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Figure 2. The AB-mediated Autoinhibition of HS- and Ligand-Binding to FGFR3c Is Intrinsically Present in the Context of the Isolated FGFR3c
Ectodomain
(A and B) Representative SPR sensorgrams, illustrating binding of (A) the D1-AB-D2-D3 and (B) D1-D2-D3DAB/linker FGFR3c isoforms to heparin. Biotinylated
heparin was immobilized on a streptavidin-coated biosensor chip, and increasing concentrations of the receptor ectodomains were passed over the chip.
(C and D) Representative SPR sensorgrams showing binding of (C) D1-AB-D2-D3, and (D) D1-D2-D3DAB/linker to FGF1.
(E and F) Representative SPR sensorgrams illustrating binding of (E) D1-AB-D2-D3 and (F) D1-D2-D3DAB/linker to FGF8b. FGF1 and FGF8b were immobilized via
random amine coupling onto a CM5 biosensor chip, and increasing concentrations of the ectodomains were flowed over the chip. See also Figure S2.
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D3DAB/linker in the HSQC spectra.
To identify this ‘‘problematic’’ Ig domain, we generated the
following domains/segments of FGFR3c: D1, D1-AB-D2, D1-
D2DAB/linker, D1-AB/linker, D2, D3, and D2-D3 (Figure S2A; Table
S1). The 1H-15N-HSQCspectra of all the receptor fragments lack-
ing D3 exhibited well-dispersed peaks having uniform line width
and intensities (FiguresS2D–S2H). In contrast, theHSQCspectra
of the isolated D3 (Figure S2I) or the D2-D3 fragment (Figure S2J)
exhibited a cluster of peaks in the randomcoil region, reminiscent
of the HSQC spectrum of the D1-AB-D2-D3 construct (compare
Figures S2I and S2J with Figure S2B). These data, therefore,
flagged D3 as the cause of ‘‘bad’’ behavior of the D1-AB-D2-D3
and D1-D2-D3DAB/linker constructs in HSQC analysis.
AB-Mediated Autoinhibition of HS Binding Is Intact
in the D1-AB-D2 Fragment of FGFR3c
Based on the HSQC profiles, the D1-AB-D2 construct is the
longest well-behaved FGFR3 region tractable for structural80 Structure 20, 77–88, January 11, 2012 ª2012 Elsevier Ltd All rightcharacterization by NMR. However, the D1-AB-D2 construct
cannot be used for investigation of the AB/linker-imposed auto-
inhibition of ligand binding because X-ray crystal structures of
several FGF-FGFR complexes solved by others and us have
clearly shown that both D2 and D3 of FGFR are required for
ligand binding (Olsen et al., 2006; Plotnikov et al., 1999, 2000;
Stauber et al., 2000; Yeh et al., 2003). Since binding of FGFR
to HS/heparin is only mediated by D2 (Figures 1A and 1B;
Mohammadi et al., 2005a; Schlessinger et al., 2000), we tested
whether the AB/linker-mediated autoinhibition of HS binding to
D2 still takes place in the context of the D1-AB-D2 construct
by comparing the heparin/HS-binding affinity of D1-AB-D2 and
D1-D2DAB/linker using SPR spectroscopy. D1-AB-D2 exhibited
almost 3-fold lower affinity for heparin than D1-D2DAB/linker (Table
1; Figures S3A and S3B). Importantly, the D1-AB-D2 and D1-
AB-D2-D3 constructs experienced a similar degree of loss in
HS-binding affinity relative to their AB/linker-lacking counter-
parts, indicating that AB/linker-mediated autoinhibition of HS
binding to receptor is fully intact in the D1-AB-D2 constructs reserved
Table 1. Dissociation Constants (Kds) Obtained From SPR
Analysis
Receptor Ectodomain
Fragment Heparin FGF1 FGF8
D1-AB-D2 (FGFR3c) 162 Not studied Not studied
D1-D2DAB/linker (FGFR3c) 61 Not studied Not Studied
D1-AB11ALA-D2 (FGFR3c) 53 Not studied Not studied
D1-AB-D2-D3 (FGFR3c) 197 622 888
D1-D2-D3DAB/linker (FGFR3c) 72 310 367
D1-AB11ALA-D2-D3
(FGFR3c)
78 344 440
AB-D2-D3 (FGFR1c) 207 1230 Not measurable
D1-AB-D2-D3 (FGFR1c) 196 2000 Not measurable
D1-D2-D3DAB (FGFR1c) 68 265 390
D1-AB13ALA-D2-D3
(FGFR1c)
66 268 329
All Kd values are in nanomolar (nM). See also Figures S3 and S4.
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we concluded that the D1-AB-D2 construct is suitable for struc-
tural characterization of the role of the AB/linker in FGFR
autoinhibition.
AB Engages in cis the HBS on D2 of FGFR3c
To elucidate the mechanism by which the AB/linker suppresses
HS-binding affinity of the D2 region, the backbone resonances of
both D1-AB-D2 and D1-D2DAB/linker constructs were assigned.
The 1H-15N HSQC spectra of D1-AB-D2 and D1-D2DAB/linker
were overlaid, and residues in the D1 and D2 domains that
undergo chemical shift changes due to deletion (alternative
splicing) of the AB/linker region were identified using a chemical
shift difference cutoff of 0.08 ppm (Figure 3A). In D1, the back-
bone resonances of A36, Q48, L49, V50, F51, G52, S53, E58,
S100, D103, andG105were perturbed (Figure 3B-I; see also Fig-
ure 1D for primary sequence) indicating that these D1 residues
make intramolecular contacts with D2, AB/linker, or both in the
D1-AB-D2 construct. Since neither a crystal nor solution struc-
ture of FGFR3c D1 is currently available, these chemically per-
turbed D1 residues were mapped onto the solution structure of
the homologous D1 region of FGFR1c (Kiselyov et al., 2006a;
Figure 3C).
The 21 D2 residues that experienced chemical shift perturba-
tions upon deletion (alternative splicing) of the AB/linker region
included: T154, R155, E157, R158, M159, D160, K161, K162,
L163, N170, V172, R173, F174, C176, A179, G180, N181,
W188, F234, Q239, and T240 (Figure 3B-I). In Figure 3D, these
D2 residues were mapped onto the molecular surface of the
D2 domain taken from the crystal structure of FGF1 complexed
with the D2-D3 region of FGFR3c, previously solved in our labo-
ratory (PDB ID 1RY7; Olsen et al., 2004). These NMR data unam-
biguously show that D2 interacts in cis with D1 and/or the AB/
linker. Notably, five of the perturbed D2 residues, namely,
R155, R158, K161, R173, and R175, belong to the HBS of the
receptor (Figures 1B–1D). The observed chemical shift changes
of HBS residues in D2, together with the SPR data showing that
D1-AB-D2 exhibits lower HS-binding affinity than D1-D2DAB,
strongly suggest that D1, the AB/linker, or both regions engageStructure 20,in cis the HBS of D2 to suppress HS-binding affinity of the
D1-AB-D2 construct.
To determine whether D1, AB/linker, or both regions engage
the HBS on D2, we assigned backbone resonances of the D1-
AB/linker construct and compared them with the corresponding
resonances of the D1-AB/linker region from the D1-AB-D2
construct. Deletion of D2 led to perturbation of 11 residues in
the D1-AB/linker region, including E37, C119, E135, D136,
G137, E138, D139, E140, A141, E142, and D143 (Figure 3B-II).
Notably, nine out of eleven perturbed residues, namely, E135,
D136, G137, E138, D139, E140, A141, E142, and D143, belong
to the AB subregion of the AB/linker (Figure 1D), whereas only
two residues from the D1 domain, namely, E37 and C119, are
affected. These data, therefore, demonstrate that the negatively
charged residues of the AB subregion of the AB/linker electro-
statically engage the positively charged HBS on D2 in cis,
whereas D1 makes only minor contacts with D2.
To fully nail down that the AB subregion is the primary region of
the AB/linker that binds D2 intramolecularly, we made a mutated
version of D1-AB-D2, in which the eleven primarily acidic resi-
dues (residues D133 to D143) of the AB subregion (Figure 1D)
were collectively mutated to alanines (D1-AB11ALA-D2; Fig-
ure 3E; Table S1). Backbone resonances of the D1 and D2
domains of this construct were assigned and compared with
those of the native D1-AB-D2 construct (Figure 3B-III). This
chemical shift difference analysis shows that substitution of the
AB residues for alanines induces chemical shift perturbations
of the very same D2 residues, including the HBS residues, which
are perturbed when the AB/linker region altogether is deleted.
This conclusion is further corroborated when one compares
the chemical shift changes in the D2 region between D1-
AB11ALA-D2, D1-D2DAB/linker, and the isolated D2 (Figures 3B-
IV and 3B-V). This comparison shows essentially no chemical
shift differences between these three constructs at the D2
region, confirming that the AB subregion is the primary region
of the AB/linker that engages the HBS region of D2 to suppress
HS-binding affinity of FGFR.
In order to show that the AB/linker competes with binding of
HS to the HBS on D2, increasing concentrations of unlabeled
sucrose octasulfate (SOS) were titrated into 15N-labeled D1-
AB-D2, and 1H-15N-HSQC spectra of D1-AB-D2 were recorded.
Because of difficulties in obtaining homogeneous HS samples,
SOS is often used as an analog in structural characterization of
FGF and FGFR interactions with HS. Analysis of the HSQC
spectra showed that the addition of SOS to D1-AB-D2 results
in perturbations of residues in the HBS of D2 (R158, K161,
R173, and R175) and in the AB/linker (E135, D136, G137,
E142, D143, V146, D147, and T148; Figure 3B-VI). These data
demonstrate that the addition of SOS dissociates the intramo-
lecular autoinhibitory contacts between the AB/linker and the
HBS on D2. Taken together, these systematic chemical shift
difference analyses show that the AB subregion is the principal
region of the AB/linker that engages the HBS on D2 to suppress
the ability of FGFR to bind to HS. Consistent with this conclusion,
D1-AB11ALA-D2 and D1-D2DAB/linker bind heparin with about
3-fold greater affinity than D1-AB-D2 (Table 1; Figures S3A,
S3B, and S4A).
To extend our findings to the full-length FGFR3c ectodo-
main, we made the D1-AB11ALA-D2-D3 construct (Figure 3E;77–88, January 11, 2012 ª2012 Elsevier Ltd All rights reserved 81
Figure 3. The AB/Linker Region Interacts Intramolecularly with the HBS of D2 in the D1-AB-D2 Fragment of FGFR3c
(A) Overlaid 1H-15N-HSQC spectra of D1-AB-D2 (in black) and D1-D2DAB/linker (in red) isoforms. Some of the residues experiencing significant chemical shift
changes are labeled.
The histograms in panel (B) show backbone amide chemical shift differences (Dd) between (I) D1-AB-D2 and D1-D2DAB/linker; (II) D1-AB-D2 and D1-AB/
linker; (III) D1-AB-D2 and D1-AB11ALA-D2; (IV) D1-AB11ALA-D2 and D1-D2DAB/linker; and (V) D1-AB11ALA-D2 and D2. (VI) The chemical shift differences
(Dd) induced in D1-AB-D2 (100 mM) upon addition of SOS (200 mM). Regions experiencing chemical shift changes greater than 0.08 ppm are highlighted
by green and red stripes. Note that residues 204-211, which belong to the secondary ligand-binding site in D2 (Plotnikov et al., 1999), could not be
assigned because of their intermediate time scale exchange rate. The significant chemical shift changes observed at the N- and C-terminal regions are
expected because of the flexibility of these regions and therefore are not colored. The blue, red, and gray bars denote residues in the D2 domain that
participate in HS binding, primary ligand binding, and receptor-receptor interaction, respectively. These perturbed residues are color-coded as in
Figure 1D.
(C and D) Residues in D1 and D2, experiencing chemical shift perturbations upon deletion/alternative splicing of the AB/linker from D1-AB-D2, are mapped onto
the solution structure of FGFR1 D1 domain (PDB ID 2CKN; Kiselyov et al., 2006a) (C) and D2 domain taken from the crystal structure of FGF1-FGFR3c (PDB ID
1RY7; Olsen et al., 2004) (D). The molecular surfaces of D1 and D2 are colored orange and green, respectively, and the perturbed residues are highlighted in
yellow. Note that the deletion of the AB/linker region from D1-AB-D2 induces chemical shift perturbations of D1 residues, whereas selective substitution of the
Structure
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Acid Box-Mediated FGF Receptor AutoinhibitionTable S1) and compared its HS binding affinity to that of D1-
AB-D2-D3 and D1-D2-D3DAB/linker using SPR spectroscopy (Fig-
ure S4B). D1-AB11ALA-D2-D3 and D1-D2-D3DAB/linker boundHS
with similar affinities (Kds of 78 nM and 72 nM, respectively),
which were almost 3-fold greater than that of D1-AB-D2-D3
(Table 1; Figures 2A and 2B; Figure S4B). These data show
that as in the D1-AB-D2 construct, the AB subregion interacts
with D2 to suppress HS-binding affinity of the full-length FGFR3c
ectodomain.
Intramolecular Interaction of the AB Subregion
with the HBS of D2 Sterically Suppresses Binding
Affinity of FGFR3c for Ligands
Analysis of our chemical shift mapping data show that the cis
interaction of the AB subregion with the HBS on D2 also per-
turbs the chemical shift of several D2 residues situated either
within (D160) or adjacent to the primary ligand-binding site on
D2 (Figure 3B-III). In fact this is anticipated because in the crystal
structures of FGF-FGFR complexes the HS-binding site and the
primary ligand-binding site on the D2 domain are adjacent to
each other (Figure 4A; see also Figure 1D). We inferred from
these observations that the interaction of the AB subregion
with the HBS on D2 could also sterically interfere with ligand
binding to FGFR. To explore this possibility, ligand-binding
affinity of the D1-AB11ALA-D2-D3 construct was compared to
that of D1-AB-D2-D3 and D1-D2-D3DAB/linker using SPR spec-
troscopy. The D1-AB11ALA-D2-D3 and D1-D2-D3DAB/linker con-
structs bound FGF1 and FGF8b with 2-fold greater affinities
than did D1-AB-D2-D3 (Table 1; Figures 2C–2F, 4B, and 4C).
These data indicate that the cis AB:HBS interaction sterically
autoinhibits ligand binding to the receptor, providing a second
level of autoinhibition.
D1 Is Dispensable for Autoinhibition of HS Binding
to FGFR1c but Plays a Minor Role in Autoinhibition
of Ligand Binding to FGFR1c
We next dissected the role of D1 in FGFR autoinhibition. To
do so, we decided to make an FGFR3c construct lacking D1
(AB-D2-D3) and compare, by SPR spectroscopy, its HS- and
ligand-binding affinities to those of D1-AB-D2-D3. We reasoned
that if the AB subregion alone was sufficient for autoinhibition
of HS- and ligand-binding to the receptor, then deletion of D1
should have no impact on receptor autoinhibition, that is, the
AB-D2-D3 construct should have similar HS- and ligand-binding
affinities as the D1-AB-D2-D3 construct. Since the AB-D2-D3
fragment of FGFR3c could not be expressed in E. coli, we
switched to the analogous construct of FGFR1c (Table S1). As
controls, an FGFR1c ectodomain construct lacking the AB
subregion of the AB/linker (D1-D2-D3DAB) and an FGFR1c con-
struct in which the acidic residues of the AB subregion were re-
placed by alanines (D1-AB13ALA-D2-D3) were used (Table S1).
FGFR1c D1-AB-D2-D3 bound heparin with about 3-fold
lower affinity than did both D1-D2-D3DAB and D1-AB13ALA-
D2-D3 (Table 1; Figures S5A, S5C, and S5D). Furthermore, theacidic residues in the AB of the AB/linker region with alanines does not perturb a
therefore, suggest that D1 interacts with the flanking regions of the AB subregio
(E) Schematic representation and amino acid boundaries of the alanine-substitute
D1, D2, D3, and the mutated AB region are colored orange, green, blue, and wh
Structure 20,D1-AB-D2-D3 construct bound FGF1 with an approximately
7-fold lower affinity than the D1-D2-D3DAB and D1-AB13ALA-
D2-D3 constructs (Table 1; Figures S6A–S6D). The affinity of
the D1-AB-D2-D3 construct for FGF8b was too weak to be reli-
ably measured (Figure S6E), whereas the D1-D2-D3DAB and
D1-AB13ALA-D2-D3 constructs bound FGF8b with comparable
affinity (Table 1; Figures S6G and S6H). These control experi-
ments also convincingly demonstrate that, akin to FGFR3c,
the presence of the AB subregion suppresses both HS- and
ligand-binding affinity of FGFR1c.
Next, we measured the heparin- and ligand-binding affinities
of the AB-D2-D3 construct. As shown in Figure S5, the AB-D2-
D3 construct of FGFR1c binds heparin with similar affinity as
the D1-AB-D2-D3 construct, indicating that D1 does not play
any role in the autoinhibition of HS binding to the receptor
(Table 1; Figures S5A and S5B). Only subtle differences
in ligand-binding affinity were seen between the AB-D2-D3 and
D1-AB-D2-D3 constructs, suggesting that autoinhibition of
ligand-binding to the receptor remains nearly intact in the AB-
D2-D3 construct. AB-D2-D3 bound FGF1 with slightly greater
affinity than did D1-AB-D2-D3 (Table 1; Figures S6A and S6B).
The SPR data for FGF8b binding to the D1-AB-D2-D3 and
AB-D2-D3 constructs could not be fitted to derive dissociation
constants. However, qualitative analysis of the sensorgrams
indicates that AB-D2-D3 also binds FGF8b with slightly greater
affinity than does D1-AB-D2-D3. This is evidenced by the fact
that at any given concentration of either of the two ectodomain
constructs, the FGF8b:AB-D2-D3 complex elicits a greater bind-
ing response than the FGF8b:D1-AB-D2-D3 complex (compare
Figure S6E with Figure S6F). Taken together, these data demon-
strate that D1 is dispensable for autoinhibition of HS binding to
FGFR butmay play aminor role in autoinhibition of ligand binding
to FGFR.
The AB Subregion Interacts Transiently with the HBS on
D2 of FGFR3c
Collectively, our NMR and SPR data show that the AB subregion
interacts in cis with the HBS on the D2 domain to directly
compete with HS binding and also to sterically inhibit ligand
binding to FGFRs. Lastly, we studied the dynamics of the cis
AB:D2 interaction by collecting heteronuclear NOE data on
D1-AB-D2. As shown in Figure 5, the NOE intensities of the
AB/linker residues are significantly lower than those belonging
to the residues in the well-structured D1 and D2 domains. These
data show that the AB/linker is flexible, indicating that the inter-
action between the AB subregion and the HBS on D2 is of a tran-
sient nature.
DISCUSSION
In this report we show that the AB subregion plays a key role in
FGFR autoinhibition by engaging in cis the HBS of the receptor
D2 domain and thereby suppressing HS and FGF binding to
the receptor. Because of the close proximity of HS binding andny residues in D1 (compare Figure 3B-I with Figure 3B-II). These observations,
n of the AB/linker.
d version of FGFR3c constructs generated for chemical shift mapping analyses.
ite, respectively. See Table S1 and Figures S5–S7.
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Figure 4. The AB:HBS Interaction Sterically Suppresses Ligand-
Binding Affinity of FGFR3c Because of the Close Proximity of
Heparin-Binding Site and Primary Ligand-Binding Sites on the D2
Domain
(A) Residues situated in the primary ligand-, the heparin-, and the receptor–
receptor binding sites are mapped onto the crystal structure of the D2 domain
(PDB ID 1RY7; Olsen et al., 2004). These residues are highlighted in red, blue,
and gray, respectively and color-coded are as in Figure 1D. The D2 residues
within the yellow boundary are perturbed upon interaction of the AB subregion.
(B and C) Representative SPR sensorgrams illustrating binding of D1-
AB11ALA-D2-D3 to FGF1 (B) and FGF8b (C). D1-AB11ALA-D2-D3 binds FGF1
and FGF8b with Kds of 344 nM and 440 nM, respectively. By comparison, D1-
AB-D2-D3 binds FGF1 and FGF8b with Kds of 622 nM and 888 nM, respec-
tively (Figures 2C and 2E). FGF1 and FGF8b were immobilized on a CM5
biosensor chip, and increasing concentrations of the indicated receptor
ectodomains were flowed over the chip.
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84 Structure 20, 77–88, January 11, 2012 ª2012 Elsevier Ltd All rightreceptor-receptor binding sites on D2, the cis AB:HBS inter-
action also perturbs N170, a key residue that mediates
receptor-receptor interaction in the 2:2:2 FGF-FGFR-HS dimer
(Figure 3B-III; see also Figure 4A). This finding implies that the
intramolecular AB:HBS interaction could also sterically interfere
with receptor-receptor binding, perhaps imposing a third level of
FGFR autoinhibition, which is autoinhibition of receptor dimer-
ization. These three levels of AB-mediated FGFR autoinhibition
act in concert to keep FGF signaling under tight control. In agree-
ment with the key role of the AB subregion in FGFR autoinhibi-
tion, sequence analysis of FGFR ectodomains shows that the
AB subregion is highly conserved among the four human FGFRs
family members and their orthologs (Figures 6A and 6B).
Based on our NMR and SPR data we propose that FGFR
exists in an equilibrium between a ‘‘closed’’ and an ‘‘open’’ con-
formation (Figure 6C). In the closed conformation, the AB subre-
gion engages the HBS of D2 and as a result HS- and ligand-
binding affinities of FGFR, and potentially receptor-receptor
interaction are suppressed (Figure 6C). Heparan sulfate and
FGF preferentially bind to the open conformation, leading to
receptor dimerization (Figure 6C). Our NOE data show that the
AB transiently interacts with D2 and suggest that the closed
and open conformations are equally populated. Thus, FGFR
autoinhibition differs from the classic autoinhibition systems,
such as the Wiskott-Aldrich syndrome protein (Buck et al.,
2004) and the Vav proto-oncoprotein (Li et al., 2008), where
over 90% of the molecules are in the autoinhibited state under
basal conditions. Our NMR and SPR data, however, suggest
that binding of AB to D2 not only suppresses HS binding but
also ligand binding and potentially direct receptor-receptor
binding necessary for dimerization. Therefore, we believe that
although the cis AB:D2 interaction is transient, the sum of these
three levels of AB-mediated FGFR autoinhibition would provide
an effective mechanism to keep FGF signaling under tight
control.
As alluded to in the introduction, McKeehan et al. proposed
that the AB/linker servesmerely as a ‘‘passive’’ tether to facilitate
the autoinhibitory intramolecular interactions of D1 with both the
HS- and the ligand-binding sites of the D2-D3 regions (Wang
et al., 1995). In support of this model, Kiselyov et al. (2006)
were able to detect a trans interaction between D1 and ligand
binding sites on D2 in NMR titration experiments, where 2 mM
D1was titrated into 0.5 mM 15N-labeled D2 and vice versa (Kise-
lyov et al., 2006b). Our data decisively show that the AB plays an
active role in FGFR autoinhibition as opposed to being merely
a ‘‘passive tether.’’ This is best exemplified by the fact that auto-
inhibition in FGFR1c and FGFR3c is solely relieved by sub-
stituting the acidic residues in the AB subregion with alanines,
without changing the length of the AB/linker (Figures S5D and
S4B). Furthermore, we do not see any evidence for intramolecu-
lar interaction between D1 and the D2-D3 region. Our chemical
shift mapping analyses show that the deletion of D2 from the
D1-AB-D2 construct induces only minor perturbations in D1
(Figure 3B-II). In addition, overlay of the HSQC spectra of
15N-labeled D1-AB/linker and D1-AB-D2-D3 shows no changes
in backbone amide chemical shifts of D1 residues (Figure S7A).
Hence, D1 does not interact in cis with D2 in either D1-AB-D2
or the intact full-length FGFR3c ectodomains. It is noteworthy
that we failed to detect a trans interaction between D1 and D2s reserved
Figure 5. The AB/Linker Region Exhibits Flexibility
in the D1-AB-D2 Fragment of FGFR3c
The 15N{1H}NOE is plotted as a function of residue number
of the D1-AB-D2 region. Error bars indicate the standard
deviation of the NOE intensity determined from three
independent measurements. Residues situated in the
well-structured D1 and D2 domains exhibit NOE >0.7. In
contrast, residues in the AB/linker region show NOE < 0.5,
indicating that this region is flexible. As expected, residues
of flexible N- and C-termini of the D1-AB-D2 fragment also
exhibit NOE <0.5. Individual domain boundaries and the
AB/linker region are indicated atop of the plot. NOEs of
four cysteines (C61, C109, C176, and C228) that form two
disulfide bridges in the well-structured regions of D1 and
D2 are labeled and highlighted in red.
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tions (Figure S7B). We would surmise that the D1 and D2
domains are connected to each other in the intact ectodomain,
so the local concentration of D1 relative to D2 will be much
greater than even the concentration at which a trans interaction
between D1 and D2 was observed (Kiselyov et al., 2006b).
Therefore, we should have readily detected a cis interaction
between D1 and D2 in our D1-AB-D2 and D1-AB-D2-D3
constructs, which are physiologically more relevant systems to
study receptor autoinhibition (Figure 3B2; Figure S7A).
Heparan sulfate is abundantly expressed in the pericellular
matrix; thus, we speculate that the AB-mediated receptor auto-
inhibition has evolved to minimize the risk of inadvertent ligand-
independent HS-mediated receptor dimerization and activation
(Figure 6C). The AB-mediated FGFR autoinhibition may also
provide a molecular explanation for the recent finding that
the FGFR3c ectodomain inhibits ligand-independent receptor
dimerization (Chen et al., 2010). We further suggest that the
AB-mediated autoinhibition may also serve as a mechanism to
reinforce FGF-binding specificity. Only specific high-affinity
ligands that are capable of overcoming the autoinhibition will
gain access to the ligand-binding site on the D2-D3 region of
receptor. In agreement with this idea, it has been previously
shown that the alternatively spliced FGFR3c isoform lacking
the AB/linker elicits a strong mitogenic response to FGF2 and
FGF4 ligands that are outside the specificity profile of the full-
length FGFR3c isoform (Shimizu et al., 2001). The three levels
of AB-mediated FGFR autoinhibition along with their effect on
FGF-binding specificity would, therefore, provide an elegant
mechanism for tight control of FGF signaling in cellular pro-
cesses, including cell proliferation and differentiation. Loss of
this autoinhibitory mechanism underlies several human disor-
ders and malignancies (Onwuazor et al., 2003; Tomlinson and
Knowles, 2010), highlighting the importance of this control
mechanism in human physiology.Structure 20, 77–88, January 1Our model of FGFR ectodomain autoinhibi-
tion differs from that of the epidermal growth
factor receptor, the only other receptor tyrosine
kinase (RTK) for which an autoinhibitory molec-
ular mechanism in the receptor ectodomain has
been elucidated to date (Cho and Leahy, 2002;
Ferguson et al., 2003). Hence, it appears that
different RTKs employ distinct autoinhibitorymechanisms that are probably fine-tuned to their specific phys-
iological functions. Loss of these autoinhibitory mechanisms is
a common culprit in human malignancies; therefore, elucidation
of these autoinhibitory molecular mechanisms of RTKs should
not only shed light onto the molecular etiology of a variety of
human diseases but also aid in the discovery of novel drugs for
their treatment.
EXPERIMENTAL PROCEDURES
Expression and Purification of FGFR Ectodomain Fragments
and FGF Ligands
Thedetails of the receptor and ligandconstructsmade for this studyare given in
Table S. A PCR splicing method was used to delete the AB/linker from the
D1-AB-D2 and D1-AB-D2-D3 fragments of FGFR3c and the AB subregion
from D1-AB-D2-D3 of FGFR1c. Alanine substitutions in the AB subregion of
D1-AB-D2-D3 (FGFR3c) and D1-AB-D2 (FGFR3c) were achieved through
multiple roundsof site-directedmutagenesis using theStratageneQuikChange
mutagenesis kit. The alanine substitution in the AB subregion of D1-AB-D2-D3
(FGFR1c) was done using a PCR-based mutagenesis method. All constructs
were expressed in E. coli BL21 (DE3) strain and purified as described in the
supplementary material. All proteins were concentrated using Amicon Ultra
centrifugal filters (Millipore, Billerica, MA, USA), and protein concentra-
tions were spectrophotometrically determined by measuring absorbance at
280 nm under denaturing conditions using extinction coefficients at 280 nm
computed by the ProtParam tool (http://ca.expasy.org/tools/protparam.
html). The final concentration of proteins in 25 mMHEPES (pH 7.5) buffer con-
taining 150 mM NaCl buffer fell within the range of 50 mM to 400 mM.
Surface Plasmon Resonance Experiments and Data Processing
SPR experiments were performed at 25C on a BIAcore 2000 instrument
(GE Healthcare, Piscataway, NJ, USA). For heparin binding experiments,
biotinylated heparin (Sigma, St. Louis, MO, USA) was noncovalently immobi-
lized on a streptavidin-coated biosensor chip (Sensor Chip SA, GE Healthcare)
at a density of approximately 180 RUs in accordance with the manufacturer’s
instructions. Various purified FGFR1c and FGFR3c ectodomain constructs
were then passed over the chip at a flow rate of 50 ml/min at five con-
centrations (25 nM, 50 nM, 100 nM, 200 nM, and 400 nM). For ligand binding
experiments, FGF homologous factor 1b (FHF1b), FGF1, and FGF8b were1, 2012 ª2012 Elsevier Ltd All rights reserved 85
Figure 6. The AB Subregion of the AB/
Linker Region Is Highly Conserved among
FGFR Orthologs and Acts at Three Levels
to Autoinhibit FGFR Signaling
(A) Sequence alignment of the AB/linker region
from the indicated FGFR3 orthologs and from fruit
fly FGFR1 and FGFR2 indicates that the AB sub-
region is conserved throughout evolution.
(B) Sequence alignment of the AB/linker region
from human FGFR1-FGFR4. The residues high-
lighted by a red box represent the AB subregion.
Periods indicate spaces introduced into the se-
quences to improve the alignments.
(C) FGFR exists in a dynamic equilibrium between
open and closed conformations. In the closed
state, the cis interaction between the AB subre-
gion and the HBS autoinhibits binding of both
HS and ligand to the FGFR, thereby suppressing
ligand- and HS-mediated receptor dimerization
and subsequent FGFR activation. The cis inter-
action may also sterically inhibit D2-mediated
receptor-receptor interaction because of close
proximity of the HS and receptor-receptor binding
sites on D2. FGF and HS bind to the open state
forming the 2:2:2 FGFR:FGF:HS signaling unit. In
the open state, the HS binds to the HBS on D2,
posing risk of HS-mediated ligand-independent
receptor dimerization.
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biosensor chip (CM5 Sensor chip, GE Healthcare) at a density of about 1300
RUs in accordance with the manufacturer’s instructions. Individual FGFR1c
and FGFR3c ectodomain constructs were then passed over the chip at
a flow rate of 50 ml/min at eight concentrations (6.25 nM, 12.5 nM, 25 nM,
50 nM, 100 nM, 200 nM, 400 nM, and 800 nM). For each concentration, the86 Structure 20, 77–88, January 11, 2012 ª2012 Elsevier Ltd All rights reservedsignal was corrected against the control surface
(captured biotin and immobilized FHF1b for the
heparin- and ligand-binding experiments, respec-
tively) to eliminate any refractive index changes
due to nonspecific binding. Association and
dissociation were allowed for 180 s each. The
chips were regenerated by HBS-EP buffer
(10 mM HEPES-NaOH [pH 7.4], 150 mM NaCl,
3 mM EDTA, 0.005% [v/v] polysorbate 20; GE
Healthcare) supplemented with 2 M NaCl. The
dissociation constants (Kds) were calculated by
equilibrium steady-state analysis using BiaEvalua-
tion software.
Backbone Assignments of D1-AB-D2,
D1-D2DAB/linker, D1-AB/linker, D2, and
D1-AB11ALA-D2 of FGFR3c
All NMR experiments were performed at 25C
using 600, 700, 800, or 900 MHz Bruker spectro-
meters equipped with cryoprobes. The concentra-
tions of the isotopically labeled D1-AB-D2 protein,
prepared in 25mMHEPES (pH 7.5) buffer contain-
ing 150 mM NaCl and 10% D2O, ranged from
200 mM to 400 mM. The 1H chemical shifts were
referenced to water at 4.75 ppm at 25C, and the
13C and 15N chemical shifts were indirectly refer-
enced using the 13C/1H and 15N/1H ratios, respec-
tively. All of the spectra were processed using
nmrPipe, visualized with nmrDraw (Delaglio et al.,
1995), and analyzed using NMRView (Johnson,2004). For the backbone assignment of the 2H, 13C, 15N labeled D1-AB-D2,
and D1-D2DAB/linker, the following TROSY-based backbone experiments
were used: 1H-15N TROSY, trHNCO, trHNCACB, and trHN(CO)CACB. The
following NMR spectra were recorded and used for the backbone assign-
ment of D1-AB/linker fragment and D2 segment: 1H-15N HSQC, HNCO,
HNCACB, and CBCA(CO)NH. D1-AB11ALA-D2 constructs were assigned by
Structure
Acid Box-Mediated FGF Receptor Autoinhibitiontransferring the backbone assignment from D1-AB/linker, D2, D1-AB-D2, and
D1-D2DAB/linker.
Chemical Shift Mapping
The following 15N-labeled fragments of FGFR3c were used for the chemical
shift mapping analysis: D1-AB/linker, D2, D1-AB-D2, D1-D2DAB/linker, D1-
AB11ALA-D2, D1-AB-D2-D3, and D1-D2-D3DAB/linker. The chemical shift
changes (Dd) were calculated using the following Equation (1):ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
ðDdHNÞ2 + ð0:25  DdNÞ2
q
;
where DdHN and DdN are the changes in the chemical shifts of
1H and 15N
dimensions, respectively, and plotted against the residue number. The cutoff
value of 0.08 was chosen based on the average chemical shift difference
observed for the entire protein.
Titration Experiments of D1-AB-D2 of FGFR3c with Unlabeled
Sucrose Octasulfate
Increasing concentrations of unlabeled SOS (0 mM, 25 mM, 50 mM, 75 mM,
100 mM, 125 mM, 150 mM, 175 mM, and 200 mM) were added continuously as
1 ml increments to a 100 mM solution of 15N-labeled D1-AB-D2 in a 25 mM
HEPES (pH 7.5) buffer containing 150 mM NaCl and 15N-HSQC spectra at
25C were recorded using Bruker spectrometers. The chemical shift differ-
ences between the two endpoints were calculated using Equation (1) and
plotted against the residue number.
Heteronuclear Overhauser Effect Measurements
The steady state 15N heteronuclear Overhauser effect (NOE) relaxation data
sets were recorded by two interleaved spectra, with and without a 4.0 s period
of proton saturation, using 48 scans per point (Farrow et al., 1994). The error
(sNOE) was determined using the following Equation (2):
sNOE =
Isat
Iunsat
2
64
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
ssat
Isat
2
+

sunsat
Iunsat
2s 375;
where Isat and Iunsat represent the measured intensities of a particular reso-
nance in the presence and absence of proton saturation, respectively; ssat
and sunsat represent the root-mean-square variation in the noise in empty
spectral regions of the spectra with and without proton saturation,
respectively.
Supplementary Information
Supplemental information includes seven figures, one table, and Supple-
mental Experimental Procedures and can be found with this article online at
doi:10.1016/j.str.2011.10.022.
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